1Rackley R, Novick A, Klein E, et al. The impact of adjuvant nephrectormy on multimodality treatment of metastic renal cell carcinoma. J Urol, 1996,152:1399-1401.
2Wagner JR, Walther MM, Linehan WM, et al. Interleukin-2 based immunotherapy for metastetic renal cell carcinoma with the kidney in place. J Urol,1999, 162:43-45.
3Walther WM, Yang JC, Pass HI, et al. Cytoreductive surgery befor high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol, 1997,158: 1675-1678.
5Russop Pj. Systemic therapy for renal cell carcinoma. J Urol,2000,163:408-417.
6Motzer RJ, Mazumdar M, Batik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.J Clin Oncol, 1999,17: 2530-2534.
3Atzpodien J,Kirchner H,IUiger H J,et al.Il-2 in combination with INF-Mpha and 5-FU verse tamorifen in metastatic renal cell carcinoma:long-term results of a randomized clinical trila[J].Br J Cancer,2001,85:1130-1136.
4Motzer RJ,Mazumdar M,Bacik J,et al.Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma[J].J Clin Oncol,1999,17:2530-2534.
5Zielinski H,Szmigielski S,Petmvich Z.Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy Mone for renal cell carcinoma[J].Am J Clin Oncol,2000,23:6-12.
6Hansmann J,Richter GM,Mallscheidt P,et al.Angiography and intervemional radiology of the kidney[J].Radiology,1999,399:361-368.
